Eyeing a blockbuster migraine market, Allergan takes an inside track on acute cases with positive PhIII
With a full slate of injectable CGRP migraine drugs positioning themselves at the finish line for FDA approvals for chronic cases, Allergan $AGN today took another big step forward with its pill for acute cases. The company hailed a Phase III win for its first late-stage test of ubrogepant, one of the migraine drugs it acquired from Merck a little more than two years ago.
Researchers say the drug hit both of the co-primary endpoints for acute migraine, with a statistically significant beat for a placebo arm in being pain free and free of most symptoms of migraine two hours after initial treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.